Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2009

WIL Research Snags Midwest BioResearch

  • WIL Research, a global CRO focused on early-stage toxicology and development, has acquired Midwest BioResearch (MBR), a Chicago-based CRO focused on preclinical drug disposition and toxicology services.

    MBR’s background is in immunoanalytical and bioassay techniques, small molecule bioanalysis, and genetic toxicology. WIL believes that this will complement its own offerings, which include chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry, and metabolism.

    “Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities,” says Christopher P. Chengelis, Ph.D., vp and CSO at WIL Research.

    With the addition of MBR, WIL Research Holding now comprises five companies with approximately 1,100 employees in the U.S., Europe, and Japan.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »